Mixed Hyperlipidemia Clinical Trial
Official title:
Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at ultrasound images taken in the carotid arteries and to look at various lipids in
the blood of people with mixed hyperlipidemia
For additional information please call: 1-800-718-1021 ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01012219 -
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
|
Phase 1 | |
Completed |
NCT00941603 -
Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
|
Phase 2 | |
Completed |
NCT04885218 -
Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia
|
Phase 3 | |
Recruiting |
NCT01974297 -
Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid
|
N/A | |
Completed |
NCT00345657 -
Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
|
Phase 4 | |
Completed |
NCT00289900 -
Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)
|
Phase 3 | |
Completed |
NCT00269217 -
Lipid Efficacy Study (0524B-022)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT01956201 -
Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin
|
Phase 3 | |
Completed |
NCT02008084 -
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
|
Phase 2 |